common procedures in metabolic therapy in nuclear medicine ... › new › ... › 2016 ›...
Post on 08-Jun-2020
0 Views
Preview:
TRANSCRIPT
Elisa Caballero Calabuig
Medicina Nuclear Hospital U. Dr. Peset Valencia
Junio 2016
Common Procedures in Metabolic Therapyin Nuclear Medicine Departments
THERAPY IN NUCLEAR MEDICINE
• Nuclear Medicine and Metabolic Therapy• Molecular Image
• Radiophysics and Radiochemistry: the radiopharmaceutical
• Detectors and Images
• References and Information Systems
• Processes en Nuclear Medicine
• Metabolic Therapy procedures: Bq = Gy• Patient adjusted vs fixed activities? Individual dosimetry?
• Things to be done to improve and expand metabolic therapy
Functional, clinical
Diagnostic90%, therapy
10%
99mTc, low E
Traceractivities,
No toxicity
Highlydependant of
technology
Physics, Chemistry,
Image
Many factorsof variability
Nuclear Medicine, molecular image
and therapy
Patient
Medicine
Therapy >10%
177Lu, 90Y, α
Therapeutic effectToxicity
DETECTORS AND IMAGES: opportunities and challenges
Dosimetry packages forRadioisotope Therapy planning
REFERENCES IN NM: standarisation
REFERENCES IN NM: process
REFERENCES IN NM: multidisciplinary teams
And the Patient
PLANNING AND DOSIMETRY IN (non)-TARGETED THERAPY
• Systemic administration: how much dose reaches the tumour?• Systemic disease, often pre-terminal: outcome assessment
• Survival, time to relapse, tumour size change…?• How to measure toxicity: peripheral blood? Bone marrow G0? GI?
External RT Metabolic therapy
So far, individual dose planning and dosimetry haven’t been common procedures
in the clinical practice. Calculation of the (approximated) absorbed dose for RIT in NM:
Uses the distribution of the activity through images over time Too many assumptions from anatomical or mathematical models, non reproducible
. standard anatomy
. uniform radiopharmaceutical distribution (body, tumour volume)
Complex and time-consuming procedures for doctors and patients Interpersonal variabilityDifficulty on assessing effects and toxicity
No evident effect on clinical outcomes
We work with data from scientific evidence (clinical trials on survival and toxicity)
PLANNING AND DOSIMETRY IN (non)-TARGETED THERAPY
Conclusion: As radionuclide therapy enters an era where patient-specific
dosimetry is used to guide treatments, accurate bone-marrow and whole-body
dosimetry will become an essential element of treatment planning. We hope that
these guidelines will provide a basis for the optimization and standardization of the
treatment of cancer with radiopharmaceuticals, which will facilitate single- and multi-centre radionuclide therapy studies.
PLANNING AND DOSIMETRY IN (non)-TARGETED THERAPY
• 131I for Hiperthyroidism
• 131I in Differentiated Thyroid cancer
• 90Y-microspheres to liver
• 177Lu-DOTATATE in neuroendocrine tumours
• 90Y-Ibritumumab-tiuxetan for Lymphoma
• 223Ra-Dichloride for blastic bone metastases
• …
METABOLIC THERAPY: why not (so far) and what for?
METABOLIC THERAPY
Prescription reviewed
Other exams / lab
Informed and writtenconsent
Patient preparation
Daily life activities survey
RP recommendations to relatives and environement
Follow-up
• Activity, dose ratio (microSV/h) andrecommendations to patient’s chart
• Other image as needed; non futile exams
• Multidisciplinary team
131I for HYPERTHYROIDISM
• Diffuse hyperthyroidism: 100-150 Gy• Hyperfunctioning nodules: 300-400 Gy• More cure rates with fixed activities
(90 % cure -60 % hypothyroidism-)• Less hypothyroidism with calculated activities
Fixed activities: 10 – 15 – 20 mCi Radiation sensitivity of the gland Estimated weight of the gland Out patient Function dynamics Aim: to cure hyperthyroidism
131I for HYPERTHYROIDISM
Response to TRAK and TSH levels Evolving functional changes
15 mCi Apr 2015 Jan 2016
131I for DIFFERENTIATED THYROID CANCER
• Fixed modulated activities• Long experience• Good clinical results, low toxicity• Aim: Survival??
131I in THYROID CANCER
Ablación Adyuvancia Terapia
Tras tiroidectomía
Células tiroides
Obligatoria?
Tras cirugía LR o
de metástasis
Micrometástasis
Células tumor
Metástasis
Ablación Dx 1 año M1 pulmón
2014 Mujer de 32 años• Papilar T3 N1 (11/24 gg) E I• 120 mCi 131I M1
131I for DIFFERENTIATED THYROID CANCER
• Different dose to tumour, remnant, lymph nodes or metastases• Uncertain clinical evolution, usually long survival• Outcome difficult to be verified (survival or long term toxicity)
131I for DIFFERENTIATED THYROID CANCER
Tumour kinetics Uptake measures difficult due
to TSHr-e or deprivation Stunning
Er
131I for DIFFERENTIATED THYROID CANCER
No measurable tumour volume Usually, planar images
2012
131I for DIFFERENTIATED THYROID CANCER
The goals of 131I in thyroid cancer are: • To kill thyroid cells (normal or tumoral)• To avoid futile treatments in refractary patients
• Different kinetics 1- 100 mCi
71 a. CPT T3 N1a M0. E III2012
Kist. Cancer 2014
100 pacientes- 124I y FDG- Tratamiento 131I- 124I vs 131I
Objetivo- Evitar ttos 131I -- Dosimetría 124I
124I FDG
131I for DIFFERENTIATED THYROID CANCER
131I for DIFFERENTIATED THYROID CANCER
We are still debatingabout the benefit of 131I on survival
131I for HIPERTHYROIDISM and DTC: external dosimetry for RP
• Daily life activities survey• microSv/h 24 h, 7, 15 d or as needed• RP recommendation of permitted
activities
131I for HIPERTHYROIDISM and DTC: personalised instructionsHOSPITAL DR. PESET, VALENCIA MEDICINA NUCLEAR TEL: 96 162 25 00
INSTRUCCIONES PERSONALIZADAS DESPUÉS DEL TRATAMIENTO CON 131I
Recomendaciones
Debe volver a Medicina Nuclear para nueva medición el día:______________
90Y to LIVER: Hepatocellular carcinoma and colorectal metastases
• Hepatocellular carcinoma and colorectal metastases
• Well tolerated
• Favorable dosimetry to medical staff
• Survival increased by 5-10 m
• Not fully integrated in the therapeutic algorithmbecause radiation and procedure fears
Braat J Nucl Med 2015; 15
90Y to LIVER: Hepatocellular carcinoma and colorectal metastases
• Hepatic tumours nourrised by hepatic artery• Activity according to tumor density, volume,
shunt and clinical situation, related to survival• All these are key points for strong variability
Braat J Nucl Med 2015; 56
Tumor/liver= 250 Gy/100 Gy
90Y to LIVER: Hepatocellular carcinoma and colorectal metastases
• Non established threshold values for liver toxicity: uniform liver: 30 Gy. BUT Tumors: 100-200 Gy
• Wide range of absorbed doses
• MAA scan to know 90Y extrahepatic passage
• Assessed by planar, SPECT, SPECT-CT?
Lambert, EJNMMI 2010
90Y to LIVER: Hepatocellular carcinoma and colorectal metastases
• Tumour size and volume, sometimes difficult to assess: SPECT-CT• Inhomogeneity of tumours, liver and lung• Number and intralesional spheres distribution for tumor volume
Are planning techniques able to predict therapeutic efficacity and toxicity? Options for combined therapy with QT
Braat. J Nucl Med 2015; 56
90Y to LIVER: Hepatocellular carcinoma
Braat. J Nucl Med 2015; 56
90Y to LIVER: colorectal metastases
177Lu-DOTATATE for NEUROENDOCRINE TUMOURS
• NETs are different kind of tumours• Expression of somatostatin receptors
when well differentiated• 90Y, 177Lu - Somatostatin analogues are
high affinity and specific target to SR • Metastatic or inoperable • Neoadjuvant use• Benefit on survival !! • New treatment, to be clearly positioned
33
177-Lu-Dotatate
(n=101)*
Sandostatin LAR
60 mg (n=100)*
Complete Response (n) 1 0
Partial Response (n) 17 3
Objective Response Rate (*) 18% 3%
Confidence Interval (95%) 10% - 25% 0% - 6%
Statistical Significance p = 0.0008
All patients (n=116) (n=113)
Progressive Disease 6 (5%) 27 (24%)
Stable Disease 77 (66%) 70 (62%)
(*) Exclude patients with no post-baseline scans or central response available
Objective ResponsesCurrently evaluable patients
Summary and Conclusions
34
• Final analysis : In this first prospective randomized study in patients with progressive
metastatic midgut NETs, 177Lu-Dotatate was superior to Octreotide 60 mg in terms
of:
− PFS (Not Reached vs 8.4 months, p<0.0001)
− ORR (18% vs 3%, p=0.0008)
• Interim analysis suggests increased OS (13 vs 22 deaths), to be confirmed by final
analysis
• 177Lu-Dotatate demonstrates a favorable safety profile, with no clinically relevant
findings especially regarding hematological, renal and hepatic parameters
• While few treatment options are available for patients progressing under SSAs, 177Lu-Dotatate has a major therapeutic benefit for this patient population
177Lu-DOTATATE in NEUROENDOCRINE TUMOURS
2013
Response assessment now Prospective studies are lacking Toxicity not well understood yet
177Lu-DOTA-TATE 90Y-DOTA-TOC TÁNDEM (177Lu / 90Y)
• Kidney protection with infused AA • Variable absorbed dose to kidney• 200 mCi /6-8 s (4 ciclos)
Kam, EJNMMI 2012
CICLO 1 CICLO 3
Imágenes cedidas por el H.U.P. La Fe de Valencia
177Lu-DOTATATE in NEUROENDOCRINE TUMOURS
111In-Octreótido 99mTc-Octreótido 68Ga-DOTATATE2-3 DÍAS 4 HORAS
S > 90% S: 60% S: 80% E: 94% Acc: 82.9%
177Lu-DOTATATE in NEUROENDOCRINE TUMOURS
Imágenes cedidas por el Servicio MN del C.H.Provincial de Castellón
177Lu-DOTATATE in NEUROENDOCRINE TUMOURS
111In-Octreótido 18F-FDG
Not only RECIST!
177Lu-DOTATATE in NEUROENDOCRINE TUMOURS
177Lu-DOTATATE in NEUROENDOCRINE TUMOURS
2016
90Y-IBRITUMOMAB TIUXETAN for LYMPHOMA
• CD20+ F-NHL (B-cell L), indolent subtypes • Low-grade or follicular B-cell NHL that has relapsed
during or after treatment with other anticancer drugs• 2008: Newly diagnosed follicular NHL following
a response to initial anticancer therapy• Exclusion criteria: bone marrow supression• 11-15 MBq/kg• Potential severe toxicity, but manageable• Currently, not frequently prescribed
90Y-IBRITUMOMAB TIUXETAN for LYMPHOMA
90Y-IBRITUMOMAB TIUXETAN for LYMPHOMA
• 111In-Zevalin after Rituximab 250 mg/m2• Planar Images and blood samples at 8 points• MIRDOSE3 software program
• Individual patient dosimetry non predictivefor 90Y Zevalin toxicity with current methods
90Y-IBRITUMOMAB TIUXETAN for LYMPHOMA
223Ra for BONE METASTASES
• Activity / kg• Aim:
• Survival• Individual efficacy
has to be shown
223Ra for BONE METASTASES
• 50 kBq/Kg, other schemes are under study
• The first pass is to check proper distribution with multichannel detector
• Peak 82, 154, 269, 351 KeV• Window 10%• HE• 4 cm/min 10 min• 4 h. post administration
223Ra for BONE METASTASES
0
400
800
1200
1600
2000
Basal pre-2ºc pre-3ºc pre-4ºc pre-5ºc pre-6ºc fin de tto
Va
lor
FA
(U
I/l)
Pac 2 Pac 4 Pac 6 Pac 8 Pac 9 Pac 10 Pac 13
Efficacy: ALP change from abnormal basal ALP
FA basal normal
(40-150 UI/l)
n: 6
FA basal
aumentada
n: 7
Reducción FA 85.7 %
223Ra for BONE METASTASES
Pain relief: Visual Analogue Scale (VAS)
0
1
2
3
4
5
6
7
8
9
10
pre-1º pre-2º pre-3º pre-4º pre-5º pre-6º fin tto
EV
A
Título del eje
Pac 1 Pac 2 Pac 3 Pac 4 Pac 6 Pac 7
Pac 8 Pac 9 Pac 10 Pac 11 Pac 12
Pacientes
analizados
↓ EVA EVA
estable
↑ EVA
n: 11 8 (73 %) 2 (18 %) 1 (9 %)
223Ra for BONE METASTASES
223Ra toxicity per patient (n: 12)
Toxicidad
hematológica y no
hematológica
Todos los
grados
G3 G4
Anemia 6 (50 %) 1 (8.3 %) -
Trombocitopenia 2 (16.7 %) 1 (8.3 %) -
Neutropenia 1 (8.3 %) - -
Náuseas 2 (16.7 %) - -
Vómitos - - -
Diarrea 3 (25 %) - -
Estreñimiento - - -
Disgeusia 1 (8.3 %) - -
223Ra for BONE METASTASES
Improvement/worsening pattern after 3 cycles (some kind of response: 86 %)
223Ra for BONE METASTASES
Baseline HDP bone scan HDP After 3 cycles 223Ra
OTHER
2008
2003
• Necessarily multidisciplinar: clinical specialist, NM, radiopharmacist, physicistCollaborative, non competitive
WORK IN PROGRESS: dose planning and dosimetry
• Challenging complex systems: from planar images to… Tumor: genetic profile, vascular, angiogenesis, heterogeneity
Vector: improved systems AG-AB, devices, administration ways
RF: other more precise and selective
Sinergias: RT, ChT, AA
Detectores: enfermedad mínima
Imagen: SPECT-CT, PET-CT
Paciente: factores clínicos
Método: modelos matemáticos, “planning helpers”, 3D
Comprensión de micro-nanodosimetría
Metrología: datos
• Dosimetry procedures should be included on the list of activities of a NM department, and time and economic valuation should be assigned
• Integrating projects: Clinicians - Nuclear Medicine - Physicists - Radiopharmacists
• Processes design for diagnosis and therapy• Data Information
• Patient selection
• Outcome selection and assessment (max dose to tumor or min dose for toxicity?)
ACTIONS: dose planning and dosimetry
Gracias
top related